Beam Therapeutics (BEAM) News Today $23.44 +0.04 (+0.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Avanza Fonder AB Invests $1.25 Million in Beam Therapeutics Inc. (NASDAQ:BEAM)Avanza Fonder AB purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,285 shares of the company's stock, valued at apJanuary 20 at 3:52 AM | marketbeat.comCT approves $80M Danbury cancer center using ‘new and evolving’ proton therapy after 5-year battleJanuary 19 at 7:03 PM | msn.comBeam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twelve analysts that are currently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have assigneJanuary 19 at 2:19 AM | marketbeat.comState-of-the-art proton beam cancer treatment is coming to Connecticut for the first timeJanuary 19 at 12:21 AM | msn.comBeam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestonesJanuary 16, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Trading Down 8% - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Shares Down 8% - Should You Sell?January 15, 2025 | marketbeat.comBeam Therapeutics (NASDAQ:BEAM) Earns Outperform Rating from WedbushJanuary 15, 2025 | americanbankingnews.comBernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM)January 15, 2025 | markets.businessinsider.comBeam Therapeutics (BEAM) Gets a Hold from Bank of America SecuritiesJanuary 15, 2025 | markets.businessinsider.comBeam Therapeutics: Strong Pipeline and Strategic Global Expansion Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comBeam Therapeutics Positioned for Growth: Strong Pipeline and Financial Resilience Drive Buy RatingJanuary 14, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at WedbushWedbush reiterated an "outperform" rating and issued a $57.00 target price on shares of Beam Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comBeam Therapeutics outlines key 2025 anticipated catalystsJanuary 13, 2025 | markets.businessinsider.comBeam Therapeutics sees cash runway into 2027January 13, 2025 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Stock Price Down 8% - What's Next?Beam Therapeutics (NASDAQ:BEAM) Trading Down 8% - Here's What HappenedJanuary 13, 2025 | marketbeat.comBeam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsJanuary 13, 2025 | globenewswire.comBeam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 18.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 639,238 shares of the company's stock after seJanuary 11, 2025 | marketbeat.comPrecision gene editing could prevent vision loss from Stargardt diseaseJanuary 10, 2025 | msn.comBeam Therapeutics upgraded to Outperform from Market Perform at BernsteinJanuary 8, 2025 | markets.businessinsider.comBeam Therapeutics price target raised to $37 from $35 at BernsteinJanuary 7, 2025 | markets.businessinsider.comBeam upgraded by Bernstein ahead of AATD dataJanuary 7, 2025 | msn.comBeam Therapeutics (NASDAQ:BEAM) Trading Up 6.7% - Here's What HappenedBeam Therapeutics (NASDAQ:BEAM) Shares Up 6.7% - Should You Buy?January 7, 2025 | marketbeat.comInsider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells 1,241 Shares of StockJanuary 7, 2025 | insidertrades.comBeam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells $30,627.88 in StockBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) insider Christine Bellon sold 1,241 shares of the company's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the sale, the insider now owns 102,968 shares of the company's stock, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.January 6, 2025 | marketbeat.comWhy Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comBeam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comBeam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.com‘The Beam’ Used to Celebrate Sacramento Kings Wins Inspires a New De’Aaron Fox Shoe ColorwayDecember 28, 2024 | msn.comBeam Therapeutics (NASDAQ:BEAM) Trading Down 2.6% - Time to Sell?Beam Therapeutics (NASDAQ:BEAM) Shares Down 2.6% - Time to Sell?December 26, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of "Moderate Buy" from AnalystsBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating aDecember 25, 2024 | marketbeat.comGeode Capital Management LLC Raises Position in Beam Therapeutics Inc. (NASDAQ:BEAM)Geode Capital Management LLC increased its stake in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 4.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,807,683 shares of the company's stock after purchasing an additiDecember 24, 2024 | marketbeat.comBeam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comState Street Corp Increases Stake in Beam Therapeutics Inc. (NASDAQ:BEAM)State Street Corp raised its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 12.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 3,929,557 shares of the company's stock after purchasing an additional 437,402 shares during the perioDecember 17, 2024 | marketbeat.comBeam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Decline in Short InterestBeam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 10,680,000 shares, a drop of 10.8% from the November 15th total of 11,970,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 10.4 days.December 15, 2024 | marketbeat.comBeam Benefits triples revenue over three years, among fastest-growing U.S. tech companiesDecember 13, 2024 | bizjournals.comResearch Analysts Offer Predictions for BEAM FY2024 EarningsBeam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, December 10th. Cantor Fitzgerald analyst R. Bienkowski expects that thDecember 12, 2024 | marketbeat.comWhy Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short SellersDecember 11, 2024 | finance.yahoo.comBeam Therapeutics (NASDAQ:BEAM) Raised to Hold at Cantor FitzgeraldCantor Fitzgerald raised shares of Beam Therapeutics to a "hold" rating in a report on Tuesday.December 11, 2024 | marketbeat.comPromising Pipeline Developments and Market Potential Drive Buy Rating for Beam TherapeuticsDecember 10, 2024 | markets.businessinsider.comBeam Therapeutics: Strong Buy Rating Backed by Promising BEAM-101 Clinical Data in Sickle Cell DiseaseDecember 10, 2024 | markets.businessinsider.comPromising Early Data and Innovative Approaches Lead to Buy Rating for Beam TherapeuticsDecember 9, 2024 | markets.businessinsider.comBeam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingDecember 8, 2024 | globenewswire.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Charles Schwab Investment Management Inc. raised its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 629,492 shares of the compDecember 8, 2024 | marketbeat.comBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingDecember 7, 2024 | globenewswire.com20,800 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 20,800 shares of the company's stock, valued at approximately $510,000. SeverDecember 7, 2024 | marketbeat.comBeam Therapeutics Names Sravan K. Emany as CFODecember 6, 2024 | markets.businessinsider.comBeam Therapeutics (NASDAQ:BEAM) Shares Up 8.6% - Still a Buy?Beam Therapeutics (NASDAQ:BEAM) Trading Up 8.6% - Here's What HappenedDecember 6, 2024 | marketbeat.comBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerDecember 6, 2024 | globenewswire.comBeam Therapeutics Strengthens Board with Pharma VeteranDecember 5, 2024 | markets.businessinsider.comRedmile Group LLC Lowers Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM)Redmile Group LLC trimmed its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 5.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,611,013 shares of the company's stock after selling 92,048 shaDecember 5, 2024 | marketbeat.com Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Media Mentions By Week BEAM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BEAM News Sentiment▼0.230.44▲Average Medical News Sentiment BEAM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BEAM Articles This Week▼116▲BEAM Articles Average Week Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News RVMD News BBIO News LNTH News LEGN News ELAN News CYTK News NUVL News GRFS News TGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BEAM) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts